Oxis Turbukhaler, 4.5 mcg/dose, 60 doses

Active ingredient

How to take, the dosage

Interaction

Special studies on the study of drug interactions of Oxis Turbukhaler with other drugs have not been conducted.

In concomitant use with other sympathomimetics (ephedrine) Oxys Turbukhaler may increase the side effects of the latter.

Concomitant use with xanthine derivatives, GCS or diuretics (thiazide and “loop” diuretics) may increase hypokalemia. Hypokalemia may increase the risk of arrhythmias in patients receiving cardiac glycosides.

The concomitant use of Oxis Turbukhaler with QTc prolonging drugs (including antihistamines: terfenadine, astemizole, misolastine; antiarrhythmic drugs: quinidine, disopyramide, procainamide ; erythromycin and tricyclic antidepressants) may increase the risk of ventricular arrhythmias.

There is a risk of arrhythmias in patients receiving Oxis Turbukhaler and concomitant anesthesia with halogenated hydrocarbons.

Beta-adrenoblockers may partially or completely block the action of the drug (especially when non-selective ?-adrenoreceptors are used). Therefore, Oxis Turbukhaler should not be administered together with beta-adrenoblockers (including eye drops) except in extreme cases of co-administration.

Special Instructions

The formoterol contained in the medication enters the patient’s airway with the air currents when actively inhaling through the Turbulator mouthpiece. It is important to clearly instruct the patient to take deep and strong breaths through the mouthpiece to ensure that the optimal dose of the medication reaches the airway.

The patient should also be instructed to never chew or chew on the mouthpiece, and not to use the Turbuhaler if the mouthpiece is damaged or if the mouthpiece becomes detached from the Turbuhaler body.

The patient may not taste or feel the medication after using the Oxis Turbukhaler due to the small amount delivered.

Patients with bronchial asthma who regularly take beta 2 -adrenomimetics should be considered for optimal anti-inflammatory therapy with corticosteroids. Patients should be advised to continue anti-inflammatory therapy even when improvement occurs after taking Oxis Turbukhaler. Persistence of symptoms or the need to increase the dose of beta 2-adrenomimetics is an indication that the patient’s condition is worsening and requires a review of anti-asthmatic therapy.

Do not initiate treatment with Oxis Turbukhaler or increase its dose if the condition worsens.

The maximum daily dose of the drug should not be exceeded. There are no safety data on long-term continuous use of the drug at higher doses, such as 36 mcg/day in adults and 18 mcg/day in children with bronchial asthma, and 18 mcg/day in patients with COPD.

The frequent use of the drug for prophylaxis of exercise-induced bronchial asthma symptoms may indicate insufficient control of the course of the disease and may warrant a review of the treatment regimen used, as well as an evaluation of the patient’s adherence to the applicable therapy regimen. If the need for prevention of exercise-induced bronchial asthma symptoms occurs multiple times in one week with adequate supportive therapy (GCS, long-acting beta 2-adrenomimetics), a review of the current treatment regimen by the specialist is necessary.

In diabetes mellitus, blood glucose concentrations should be monitored at the start of treatment, since beta 2-adrenomimetics have a hyperglycemic effect.

The use of beta 2 -adrenomimetics can potentially lead to severe hypokalemia. Particular caution should be exercised during exacerbations of severe bronchial asthma because the risk of hypokalemia may increase with hypoxia . Hypokalemia may be aggravated in concomitant therapy with xanthine derivatives, steroids, diuretics. In such cases it is necessary to monitor serum potassium level.

As with other inhalation therapy, the possibility of paradoxical bronchospasm should be considered.

The delivered dose of the drug contains 450 mcg of lactose per (corresponding to 600 mcg in the measured dose). This amount usually does not cause problems in people with lactose intolerance .

Perhaps for use in patients with hepatic impairment: No special dosing is necessary for patients with hepatic impairment when the recommended doses of the drug are administered.

Application for renal impairment: Patients with renal impairment do not require special dose selection when prescribing the recommended doses of the drug.

Pediatric use: The drug should not be administered to children under 6 years of age because there is insufficient information for this age group.

Impact on driving and operating ability: Oxis Turbukhaler does not affect the ability to concentrate and speed of psychomotor reactions.

Contraindications

With caution: Prescribe the drug in patients with thyrotoxicosis, pheochromocytoma, diabetes, hypertrophic obstructive cardiomyopathy, idiopathic subclavian aortic stenosis, severe hypertension, aneurysm or other severe cardiovascular disease, such as coronary artery disease, tachyarrhythmias or severe heart failure.

Side effects

Frequent (>1/100)

Central nervous system: headache

Cardiovascular system: palpitations

Skeletal-muscular system: tremor

Rare (<1/100)

Central nervous system: agitation, restlessness, sleep disturbance

Skeletal-muscular system: muscle cramps

Cardiovascular system: tachycardia, changes in blood pressure

Very rare (<1/1000)

Skin: rash, urticaria, itching

Cardiovascular system: Atrial fibrillation, supraventricular tachycardia, extrasystoles

Metabolic disorders: hypokalemia/hyperkalemia

Respiratory system: bronchospasm

Tremors and palpitations are temporary and resolve during treatment. As with any inhalation therapy, paradoxical bronchospasm may develop in very rare cases.

I have described single cases of the following side effects: nausea, taste disorders, dizziness, angina pectoris, prolongation of the QTc interval, hypersensitivity reactions, changes in blood pressure, and hyperglycemia.

The use of β2-sympathomimetics may increase blood levels of insulin, free fatty acids, glycerol and ketone.

Overdose

Pregnancy use